2023
Bleeding in Critically Ill Children With Malignancy or Hematopoietic Cell Transplant: A Single-Center Prospective Cohort Study
Levasseur J, Fikse L, Mauguen A, Killinger J, Karam O, Nellis M. Bleeding in Critically Ill Children With Malignancy or Hematopoietic Cell Transplant: A Single-Center Prospective Cohort Study. Pediatric Critical Care Medicine 2023, 24: e602-e610. PMID: 37678406, PMCID: PMC10843653, DOI: 10.1097/pcc.0000000000003374.Peer-Reviewed Original ResearchConceptsProspective cohort studyBleeding episodesSevere bleedingIll childrenCohort studyCell transplantIncidence rateLaboratory valuesMinimal bleedingRadiation therapySingle-center prospective cohort studyAssociated Patient CharacteristicsHigher PICU mortalityNew bleeding episodesOnly laboratory valueHematopoietic cell transplantCritically Ill ChildrenLow platelet countSevere bleeding episodesStem cell transplantPatient demographic dataSpecialized cancer hospitalModerate bleeding episodesYears of ageLonger PICU
2017
Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry
Recht M, Rajpurkar M, Chitlur M, d'Oiron R, Zotz R, Di Minno G, Cooper D, Poon M. Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. American Journal Of Hematology 2017, 92: 646-652. PMID: 28370369, DOI: 10.1002/ajh.24741.Peer-Reviewed Original ResearchConceptsRecombinant factor VIIaGlanzmann's thrombastheniaBleeding episodesPlatelet refractorinessAntibody statusDoses of recombinant factor VIIaGlanzmann's Thrombasthenia RegistrySevere bleeding episodesAnti-platelet antibodiesUnited States Food and Drug AdministrationStates Food and Drug AdministrationFood and Drug AdministrationClinical refractorinessPerioperative bleedingPlatelet transfusionsEfficacy/safety dataEfficacy rateHemostatic treatmentTreatment patternsEfficacy dataHemostatic agentsFibrinogen receptorDrug AdministrationFactor VIIaPatientsRecognition and management of platelet-refractory bleeding in patients with Glanzmann’s thrombasthenia and other severe platelet function disorders
Chitlur M, Rajpurkar M, Recht M, Tarantino M, Yee D, Cooper D, Gunawardena S. Recognition and management of platelet-refractory bleeding in patients with Glanzmann’s thrombasthenia and other severe platelet function disorders. International Journal Of General Medicine 2017, 10: 95-99. PMID: 28435309, PMCID: PMC5388206, DOI: 10.2147/ijgm.s128953.Peer-Reviewed Original ResearchPlatelet function disordersPlatelet refractorinessGlanzmann's thrombastheniaAntiplatelet antibodiesPlatelet transfusionsDevelopment of antiplatelet antibodiesRare platelet function disorderResponse to platelet transfusionExcessive surgical bleedingFunctional disordersSevere bleeding episodesApproved treatment optionEfficacy of rFVIIaQualitative platelet disordersManagement of bleedingAdapt treatment regimensMultiple case reportsManagement of patientsEffective management of bleedingClinical refractorinessBleeding episodesSurgical bleedingPlatelet countPlatelet disordersTreatment regimens
1988
A prospective randomized trial of HLA‐matched versus mismatched single‐donor platelet transfusions in cancer patients
Messerschmidt G, Makuch R, Appelbaum F, Ungerleider R, Abrams R, O'Donnell J, Holohan T, Fontana J, Wright D, Anagnou N, Shan T, Chesbro B, Deisseroth A. A prospective randomized trial of HLA‐matched versus mismatched single‐donor platelet transfusions in cancer patients. Cancer 1988, 62: 795-801. PMID: 3293762, DOI: 10.1002/1097-0142(19880815)62:4<795::aid-cncr2820620426>3.0.co;2-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAmbulatory CareAntibody FormationBlood DonorsBlood PlateletsBlood TransfusionChildChild, PreschoolClinical Trials as TopicFemaleHemorrhageHistocompatibility TestingHumansInfantMaleMiddle AgedNeoplasmsPlatelet TransfusionProspective StudiesRandom AllocationThrombocytopeniaTransfusion ReactionConceptsSingle-donor platelet transfusionsPlatelet transfusionsCancer patientsFebrile patientsPosttransfusion incrementsThrombocytopenic cancer patientsTransfusion of HLASevere bleeding episodesMulti-institution trialNonfebrile patientsIntensive chemotherapyBleeding episodesAntiplatelet antibodiesAntibody titersSignificant thrombocytopeniaHistocompatability antigensTransfusionPatientsMismatched groupHLAThrombocytopeniaPlateletsEpisodesSeparate episodesTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply